Rigel Pharmaceutical Inc. Stock
The Rigel Pharmaceutical Inc. stock is trending slightly upwards today, with an increase of €0.004 (0.370%) compared to yesterday's price.
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Rigel Pharmaceutical Inc..
With a target price of 13 € there is potential for a 1070.12% increase which would mean more than doubling the current price of 1.11 € for Rigel Pharmaceutical Inc..
So far the community has only identified positive things for Rigel Pharmaceutical Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Rigel Pharmaceutical Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rigel Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | 0.370% | 10.878% | -9.232% | 4.221% | -20.014% | -59.079% | - |
| Evolus Inc | -0.810% | 14.019% | 1.667% | 60.526% | 34.807% | 75.540% | - |
| Ardelyx Inc. | 0.160% | 40.927% | 22.899% | 104.125% | 47.266% | 54.764% | - |
| Salarius Pharmaceuticals Inc. | -6.170% | 0.472% | -0.930% | -70.417% | -23.243% | -98.346% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17
Rigel Pharma (RIGL) is a biotechnology and medical research company that plays a crucial role in finding innovative solutions for the healthcare sector. An overview of the financial statements presents a mixed picture, with some positive trends as well as areas of concern.
*Pros: *
Revenues: Rigel Pharma's total revenues have been increasing year over year, with a significant uptick between 2020 and 2021, and a steady increase in 2022. This growth in revenue indicates that the company has been successful in generating profitable sales and expanding its business.
Comments
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for RIGL provided by MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $3.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RIGL provided by MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for RIGL provided by MarketBeat